📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Aster DM Reports ₹17.69 Cr Revenue Loss Due to Kerala Nurse Strike; High Court Intervenes
Aster DM Healthcare has reported a revenue loss of ₹17.69 crore between March 8 and March 13, 2026, due to a statewide nurse strike in Kerala affecting seven of its hospitals. The Kerala High Court has intervened, directing the United Nurses Association to defer the strike until March 19 and move to mediation for wage negotiations. The company anticipates a further potential loss of ₹5.33 crore if the situation resolves by the court-mandated deadline. Management has activated contingency plans, including mobilizing staff from Karnataka, to maintain critical services.
Key Highlights
Reported revenue loss of ₹17.69 crore from March 8 to March 13, 2026
Estimated additional loss of up to ₹5.33 crore expected until March 19
Kerala High Court ordered a temporary halt to the strike and referred the dispute to mediation
Strike affected seven major hospitals including Aster Medcity and MIMS units in Kerala
Company mobilized nursing staff from neighboring Karnataka to ensure continuity of critical care
💼 Action for Investors
Investors should monitor the mediation outcome on March 19, as a permanent wage hike could impact long-term margins in the Kerala cluster. The current financial impact is manageable but highlights labor risks in a core operating region.
Aster DM Seeks Approval for Dr. Azad Moopen's Appointment & INR 1,500 Cr Loan Limit
Aster DM Healthcare has issued a postal ballot notice seeking shareholder approval for the appointment of Dr. Mandayapurath Azad Moopen as Executive Director from April 2026 to May 2028. The proposed annual remuneration is capped at INR 10 Crores, which may be paid even in the event of inadequate profits. Furthermore, the company is seeking a mandate to provide loans, guarantees, or securities up to INR 1,500 Crores to its subsidiaries and group entities. This financial limit is intended to support the growth of its core hospital, pharmacy, and diagnostic business segments over the next three years.
Key Highlights
Proposed appointment of Dr. Mandayapurath Azad Moopen as Executive Director for the period April 15, 2026, to May 28, 2028.
Annual remuneration for the Executive Director capped at INR 10 Crores, including fixed salary and variable pay.
Seeking shareholder approval for a loan and guarantee limit of up to INR 1,500 Crores for group entities under Section 185.
The INR 1,500 Crore limit will be valid for three years and restricted to core healthcare business activities.
Remote e-voting period is scheduled from March 14, 2026, to April 12, 2026, with results by April 14.
💼 Action for Investors
Investors should monitor the voting results and subsequent deployment of the INR 1,500 Crore loan limit to ensure capital is used for high-return healthcare expansions. The continuation of the founder's leadership provides stability, though the high remuneration cap during potential profit lean periods should be noted.
Aster DM Shareholders Approve Merger with Quality Care India with 96.68% Majority
Aster DM Healthcare has received a decisive 96.68% shareholder approval for its proposed merger with Quality Care India Limited (QCIL). The combined entity, to be named Aster DM Quality Care Ltd, will emerge as one of India's top three hospital chains with a massive capacity of over 10,625 beds. The transaction has already secured CCI and Stock Exchange clearances and is expected to be fully completed in the next quarter following final NCLT approvals. This merger, backed by Blackstone, significantly scales the company's operations to 39 hospitals across 9 states.
Key Highlights
96.68% of shareholders and a significant majority of creditors voted in favor of the merger scheme.
The combined entity will operate 39 hospitals with 10,625+ beds across 9 states and 28 cities.
Merger is on track for completion in the next quarter, pending final statutory NCLT approvals.
The transaction creates one of India's top three hospital chains, supported by Blackstone's institutional expertise.
The combined workforce will exceed 36,307 employees and clinicians serving millions of patients annually.
💼 Action for Investors
Investors should view this as a major positive milestone that significantly enhances the company's market share and scale. Monitor the final NCLT approval and the subsequent integration for potential operational synergies and margin improvements.
Aster DM Shareholders Approve Amalgamation with Quality Care India with 96.68% Majority
Shareholders of Aster DM Healthcare have officially approved the Scheme of Amalgamation with Quality Care India Limited (QCIL) in an NCLT-convened meeting held on March 10, 2026. The resolution saw high participation with 93% of outstanding shares being polled. A significant majority of 96.68% of total votes were cast in favor of the merger, satisfying the requirements of both the Companies Act and SEBI regulations. This approval marks a major milestone in the company's structural consolidation process.
Key Highlights
Total votes polled reached 48.18 crore, representing 93.00% of the total outstanding shares.
The merger resolution was approved by 96.68% of the total votes cast.
Public institutional shareholders supported the move with 92.76% of their votes in favor.
Public non-institutional shareholders showed near-unanimous support with 99.99% voting in favor.
The scheme involves the merger of Quality Care India Limited (Transferor) into Aster DM Healthcare (Transferee).
💼 Action for Investors
Investors should view this overwhelming shareholder approval as a positive step toward the company's growth and consolidation strategy. Monitor the final NCLT sanction and subsequent integration updates for long-term value creation.
Aster DM Appoints Founder Dr. Azad Moopen as Executive Director until May 2028
The Board of Aster DM Healthcare has approved the appointment of its founder, Dr. Azad Moopen, as an Executive Director effective from April 15, 2026, through May 28, 2028. This role is a redesignation from his current position as Managing Director, though he will continue to serve as the Chairman of the Company. The appointment is subject to shareholder approval via a postal ballot. This move is intended to ensure leadership continuity and leverage Dr. Moopen's decades of institutional knowledge and operational expertise.
Key Highlights
Dr. Azad Moopen appointed as Executive Director for a term from April 15, 2026, to May 28, 2028
Redesignated from Managing Director while retaining his position as Chairman of the Board
Appointment requires final approval from shareholders through a postal ballot process
Dr. Moopen has been associated with the company since its establishment in 1987
Leadership team includes family members Ms. Alisha Moopen (Deputy MD) and Dr. Zeba Azad Moopen (Non-Executive Director)
💼 Action for Investors
Investors should view this as a positive step for leadership stability and continuity of the company's strategic vision. No immediate action is required as the founder remains at the helm of the organization.
Aster DM Healthcare Holds Creditors Meeting for Merger with Quality Care India
Aster DM Healthcare convened a meeting of its unsecured trade creditors on March 10, 2026, to seek approval for the Scheme of Amalgamation with Quality Care India Limited. The meeting was held via video conferencing as directed by the NCLT Hyderabad bench, with 51 creditors in attendance. Remote e-voting was conducted between March 6 and March 9, 2026, to facilitate the approval process. The company is now awaiting the final scrutinizer's report to disclose the voting results to the exchanges.
Key Highlights
Meeting of unsecured trade creditors held on March 10, 2026, regarding the merger with Quality Care India Limited.
A total of 51 unsecured trade creditors participated in the NCLT-convened proceedings.
Remote e-voting was active from March 6, 2026 (9:00 AM) to March 9, 2026 (5:00 PM).
The amalgamation scheme is part of a strategic consolidation between the Transferor and Transferee companies.
💼 Action for Investors
Investors should watch for the official voting results to confirm creditor approval, which is a critical milestone for the merger. Successful amalgamation is expected to bring operational synergies and scale to Aster DM's healthcare portfolio.
Aster DM Shareholders Meet to Approve Merger with Quality Care India Limited
Aster DM Healthcare held an NCLT-convened meeting on March 10, 2026, to seek shareholder approval for the amalgamation of Quality Care India Limited into the company. The meeting was attended by 64 members via video conferencing and was chaired by an NCLT-appointed advocate. Management addressed shareholder queries regarding the rationale and salient features of the proposed scheme. The final voting results, including remote e-voting conducted between March 6-9, 2026, will be disclosed within the prescribed regulatory timelines.
Key Highlights
NCLT-convened meeting held on March 10, 2026, to approve the Scheme of Amalgamation with Quality Care India Limited.
Remote e-voting period concluded on March 9, 2026, at 5:00 P.M. IST prior to the general meeting.
A total of 64 members participated in the meeting through Video Conferencing and Other Audio Visual Means.
The scheme involves Quality Care India Limited as the Transferor Company and Aster DM Healthcare as the Transferee Company.
Final voting results and the Scrutinizer's report are expected to be disseminated to BSE and NSE shortly.
💼 Action for Investors
Investors should watch for the official voting results to confirm shareholder approval of the merger. Successful amalgamation is expected to consolidate operations and potentially enhance long-term value.
Aster DM Merger with Quality Care to Create Top 3 Hospital Chain; 10-15% EBITDA Synergy Expected
Aster DM Healthcare is advancing its merger with Quality Care India Limited to create one of India's top three hospital chains. The combined entity will operate across 9 states and 25 cities, serving approximately 2.0 million patients per quarter. Management expects the merger to generate an EBITDA upside of 10-15% through operational synergies. To address governance concerns, promoters have committed to waiving board nomination rights if their shareholding drops below 10%.
Key Highlights
Merger creates a top 3 Indian hospital chain with 6,690+ clinicians and presence in 25 cities.
Identified synergies expected to provide an EBITDA upside potential of 10-15% of FY24 pro-forma EBITDA.
Shareholders previously approved the preceding Share Swap with an overwhelming 99.998% majority.
Promoters (Aster and Blackstone) committed to governance reforms, including waiving committee nomination rights.
Final equity shareholder meeting for scheme approval scheduled for March 10, 2026.
💼 Action for Investors
Investors should view this as a major growth catalyst that significantly scales the company's footprint and margin profile. Monitor the final voting results from the March 10 meeting to confirm the merger's progression.
Aster DM Signs SHA for Sarjapur Subsidiary to Facilitate Fundraising via CCPS
Aster DM Healthcare has entered into a Shareholders' Agreement (SHA) with its wholly-owned subsidiary, Aster DM Super-specialty Hospital (Sarjapur) Private Limited. The agreement is a strategic step to facilitate the subsidiary's plan to raise capital from external investors through Compulsorily Convertible Preference Shares (CCPS). The SHA ensures Aster DM retains significant governance control, including board nomination rights and a call option on shares held by future minority investors. This move indicates a focused expansion strategy for the Sarjapur facility using external capital.
Key Highlights
Aster DM Healthcare signed a Shareholders' Agreement with its Sarjapur subsidiary on February 26, 2026.
The Sarjapur entity intends to raise funds from potential investors through the issuance of Compulsorily Convertible Preference Shares (CCPS).
Aster DM retains the right to nominate directors and holds a call option on shares held by other future shareholders.
The agreement includes strict share transfer restrictions and lock-in periods for potential external investors.
The transaction is conducted at arm's length and does not currently constitute a related party transaction under SEBI regulations.
💼 Action for Investors
Investors should view this as a positive step toward capital-efficient expansion of the Sarjapur facility. Monitor for future announcements regarding the specific amount raised and the identity of the incoming investors to gauge valuation benchmarks.
Aster DM Q3 FY26: Combined Revenue up 15% to ₹2,366 Cr; QCIL Merger on Track for Q1 FY27
Aster DM reported a 15% YoY growth in combined proforma revenue to ₹2,366 crore for Q3 FY26, with operating EBITDA rising 22% to ₹503 crore. The merger with Quality Care India Limited (QCIL) is progressing well, with NCLT approval expected by Q1 FY27, which will create a platform with over 14,710 beds. Standalone revenue grew 13% to ₹1,186 crore, supported by a 9% increase in inpatient ARPP and strong growth in Oncology and Medical Value Travel. The company maintained a healthy combined ROCE of 21% while continuing aggressive expansion plans.
Key Highlights
Combined proforma revenue grew 15% YoY to ₹2,366 crore with a 21% EBITDA margin.
Aster standalone revenue increased 13% to ₹1,186 crore, while Oncology revenue surged 27% YoY.
The merger with QCIL is on track for Q1 FY27 completion, following CCI and stock exchange approvals.
Total combined bed capacity reached 10,620+ with a pipeline to add 4,000+ more beds.
Medical Value Travel (MVT) segment grew 41% YoY, driven by a 64% increase in international footfall in Kerala.
💼 Action for Investors
Investors should monitor the upcoming shareholder meeting in late February for the QCIL merger approval, as the combined entity shows superior margins and ROCE. The stock remains a strong play on hospital consolidation and specialty mix improvement in the Indian healthcare sector.
Aster DM to Merge with Quality Care to Create India's Top 3 Hospital Chain with 10,625+ Beds
Aster DM Healthcare has announced a major merger with Blackstone-backed Quality Care India Limited (QCIL) to create a healthcare powerhouse with over 10,625 beds. The combined entity, to be named Aster DM Quality Care Limited, reported a proforma 9MFY26 revenue of INR 6,913 Cr and an Operating EBITDA of INR 1,496 Cr with a 21.6% margin. The transaction values Aster at 36.6x FY24 Adj. EBITDA, representing a 45% premium over the multiple ascribed to QCIL. The merger is expected to be EPS accretive from the first full year of operations and will be jointly controlled by Aster promoters and Blackstone.
Key Highlights
Merged entity will have 10,625+ capacity beds across 9 states and 28 cities, operating under brands like Aster, CARE Hospitals, and KIMSHEALTH.
Combined 9MFY26 financial performance shows a healthy Operating EBITDA margin of 21.6% and a RoCE of 20.7%.
Aster DM standalone 9MFY26 revenue grew to INR 3,461 Cr with ARPOB increasing to INR 51,100 from INR 44,200 YoY.
Post-merger shareholding structure will be Aster Promoters (24%), Blackstone (30.7%), and Public/Others (45.3%).
The transaction is cash-neutral and involves a share swap ratio of 977 Aster shares for every 1,000 QCIL shares.
💼 Action for Investors
Investors should view this as a transformative growth milestone that significantly enhances Aster's market position and geographical footprint. The institutional backing from Blackstone and the expected EPS accretion make this a strong long-term play in the Indian healthcare sector.
Aster DM Healthcare Schedules Creditors Meeting on March 10 for Merger with Quality Care India
Aster DM Healthcare has convened a meeting of its unsecured trade creditors on March 10, 2026, to approve the Scheme of Amalgamation with Quality Care India Limited (QCIL). This meeting follows directions from the NCLT Hyderabad Bench and previous 'no-objection' clearances from BSE and NSE received in October 2025. Creditors as of the October 31, 2025, cut-off date will participate in e-voting between March 6 and March 9, 2026. This merger is a significant step in consolidating the company's healthcare footprint in India.
Key Highlights
Meeting of Unsecured Trade Creditors scheduled for March 10, 2026, at 2:00 PM IST via VC/OAVM.
Merger involves Aster DM Healthcare Limited and Quality Care India Limited (QCIL).
Remote e-voting period is set from March 6, 2026, to March 9, 2026, for eligible creditors.
The cut-off date for determining voting rights based on outstanding dues is October 31, 2025.
The scheme previously received 'no adverse observation' letters from NSE and BSE on October 6, 2025.
💼 Action for Investors
Investors should view this as a positive procedural milestone in the merger process which aims to create a larger healthcare entity. Monitor the outcome of the creditors' meeting as it is a prerequisite for final NCLT approval.
Aster DM to Hold Shareholder Meeting on March 10 for Merger with Quality Care India
Aster DM Healthcare has scheduled an NCLT-convened meeting on March 10, 2026, to seek shareholder approval for its merger with Quality Care India Limited (QCIL). The merger will significantly expand the company's scale, as QCIL reported FY25 revenue of 3,963 Cr and an EBITDA of 855 Cr, nearly matching Aster's own financials. Post-merger, the promoter group shareholding will increase from 40.39% to 54.68%, with BCP (Blackstone) joining as a promoter. This consolidation is expected to drive operational synergies and provide strong institutional backing for long-term growth.
Key Highlights
Shareholder meeting set for March 10, 2026, to approve the Scheme of Amalgamation with QCIL.
Promoter shareholding to increase by 14.29% to reach 54.68% post-merger.
QCIL reported a high EBITDA margin of 21.5% in FY25 compared to Aster's 19.5%.
Combined entity will have a pro-forma FY25 revenue exceeding 8,100 Cr.
Cut-off date for voting eligibility is March 3, 2026, with remote e-voting starting March 6.
💼 Action for Investors
Investors should support the merger as it creates a larger, more efficient healthcare entity with improved margins and strong PE backing. Monitor the post-merger integration and the impact of the increased promoter stake on stock liquidity.
Aster DM Q3 FY26: Combined Revenue Up 15% to ₹2,366 Cr, EBITDA Grows 22%
Aster DM Healthcare reported a strong Q3 FY26 with combined proforma revenue growing 15% YoY to ₹2,366 crore. Operating EBITDA for the merged entity rose 22% YoY to ₹503 crore, reflecting improved margins of 21.3% compared to 20.1% in the previous year. The company is on track to complete its merger with Quality Care (QCIL) by Q1 FY27, which will create one of India's largest hospital networks with a total capacity of over 10,620 beds. Expansion remains aggressive with a pipeline to add 4,080+ beds in the coming years, primarily through brownfield projects.
Key Highlights
Combined proforma revenue reached ₹2,366 Cr, a 15% YoY increase driven by 9% growth in patient volumes (1.97 Mn).
Operating EBITDA grew 22% YoY to ₹503 Cr, with margins expanding 110 bps to 21.3%.
The merger with Quality Care is progressing with NCLT-directed shareholder meetings scheduled between Feb 27 and March 13, 2026.
Bed capacity increased to 10,620+ as of Dec 2025, with a long-term target of 14,710+ beds.
Kerala cluster showed exceptional performance with 20% revenue growth and 22.9% EBITDA margins.
💼 Action for Investors
Investors should focus on the strong margin expansion and the upcoming merger completion in Q1 FY27 as key catalysts. The aggressive bed expansion plan and robust ROCE of 20.7% signal long-term growth potential in the Indian healthcare space.
Aster DM Q3 FY26: Revenue up 13% to INR 1,186 Cr; Combined Proforma Revenue at INR 2,366 Cr
Aster DM Healthcare reported a steady Q3 FY26 with standalone revenue growing 13% YoY to INR 1,186 Cr and normalized PAT rising 22% to INR 98 Cr. The proforma combined entity with Quality Care India Ltd (QCIL) showed even stronger growth, with revenues reaching INR 2,366 Cr and EBITDA margins at 21%. Operational metrics improved significantly, with ARPP up 9% and Medical Value Tourism (MVT) revenue surging 41% YoY. The merger process is on track, with NCLT-directed shareholder meetings scheduled for early 2026 and completion expected in Q1 FY27.
Key Highlights
Standalone Revenue grew 13% YoY to INR 1,186 Cr; Operating EBITDA (ex-Kasaragod) rose 17% to INR 237 Cr.
Combined proforma revenue (Aster + QCIL) reached INR 2,366 Cr with a 22% YoY growth in EBITDA to INR 503 Cr.
Average Revenue Per Occupied Bed (ARPP) increased 9% YoY to INR 1,22,294, driven by improved specialty mix.
Medical Value Tourism (MVT) revenue saw a significant jump of 41% YoY, with Kerala cluster MVT growing 64%.
Merger with QCIL is on track with shareholder meetings scheduled for Feb/Mar 2026 and expected completion by Q1 FY27.
💼 Action for Investors
Investors should focus on the consistent margin expansion and the significant scale-up potential from the upcoming QCIL merger. The stock remains a strong watch as it moves toward becoming one of India's top 3 hospital chains post-merger.
Aster DM Q3 FY26 PAT Rises 10.7% to ₹55 Cr; Approves ₹129 Cr Subsidiary Loan Conversion
Aster DM Healthcare reported a steady performance for Q3 FY26 with standalone revenue growing 15.5% YoY to ₹665.75 crore. Net profit increased by 10.7% YoY to ₹55.16 crore, even after accounting for ₹7.44 crore in exceptional costs related to merger activities. The company is actively restructuring its balance sheet, converting a ₹129.35 crore inter-corporate loan into equity for its wholly-owned subsidiary. Furthermore, the NCLT has directed the company to convene meetings for the proposed merger with Quality Care India Limited, marking a significant step in its expansion strategy.
Key Highlights
Standalone Revenue from operations increased 15.5% YoY to ₹665.75 crore in Q3 FY26.
Net Profit for the quarter rose to ₹55.16 crore compared to ₹49.82 crore in the same period last year.
Approved the conversion of a ₹129.35 crore loan into equity shares for Aster DM Multispecialty Hospital Private Limited.
Increased stake in Prerana Hospital Limited (Aster Aadhar) to 98.92% following an ₹18.59 crore investment.
NCLT issued an order on January 21, 2026, to convene meetings for the merger with Quality Care India Limited (QCIL).
💼 Action for Investors
Investors should focus on the upcoming shareholder meetings regarding the Quality Care India merger, which is a key growth catalyst. The steady financial growth and internal capital restructuring indicate a strengthening Indian operations base.
Aster DM to Acquire Remaining 20.25% Stake in MIMS at INR 202 Per Share
Aster DM Healthcare's Investment and Finance Committee has approved a proposal to increase its stake in its material subsidiary, Malabar Institute of Medical Sciences (MIMS), from 79.75% to 100%. The acquisition of the remaining 20.25% stake will be a cash transaction at a price of INR 202 per share. MIMS is a highly profitable subsidiary, reporting a turnover of INR 1,118.05 crores and a profit of INR 134.51 crores for FY25. This consolidation move is expected to be completed within three months following the dispatch of the letter of offer.
Key Highlights
Plan to increase shareholding in MIMS from 79.75% to 100% via cash purchase
Acquisition price fixed at INR 202 per share for the remaining 20.25% equity
MIMS FY25 turnover stood at INR 1,118.05 Cr with a net profit of INR 134.51 Cr
MIMS has shown steady growth from a turnover of INR 899.43 Cr in FY23 to INR 1,118.05 Cr in FY25
Transaction expected to conclude within 3 months of the letter of offer dispatch
💼 Action for Investors
This is a positive move as it allows Aster DM to fully consolidate the earnings of a profitable and growing subsidiary. Investors should maintain a positive outlook as this simplifies the corporate structure and enhances bottom-line contribution from Indian operations.
Aster DM Receives NCLT Order to Convene Meetings for Merger with Quality Care India
Aster DM Healthcare has received an NCLT order to convene meetings for shareholders and unsecured creditors between February 27 and March 13, 2026, to approve its merger with Quality Care India Limited (QCIL). The combined entity, Aster DM Quality Care, will become one of India's top three hospital chains with a total capacity of over 10,360 beds. The merger has already secured CCI and Stock Exchange approvals and is expected to be completed by Q1 FY27. This consolidation, backed by Blackstone, aims to scale capacity to over 14,715 beds in the coming years.
Key Highlights
NCLT directed shareholder and creditor meetings to be held between Feb 27 and March 13, 2026
Merged entity will have 10,360+ beds, positioning it as one of India's top 3 hospital chains
Transaction has already received CCI and Stock Exchange approvals with Q1 FY27 completion target
Combined portfolio to include four major brands: Aster DM, CARE Hospitals, KIMSHEALTH, and Evercare
Long-term growth strategy aims to expand total bed capacity to approximately 14,715+ beds
💼 Action for Investors
Investors should monitor the upcoming shareholder meetings in March 2026 as this merger significantly enhances the company's scale and market position. The entry of Blackstone as a co-promoter and the massive bed expansion plan are strong long-term value drivers.
Aster DM Receives NCLT Order to Convene Shareholder Meeting for Quality Care Merger
The NCLT Hyderabad Bench has directed Aster DM Healthcare to convene meetings for equity shareholders and unsecured trade creditors between February 27 and March 13, 2026, to approve its merger with Quality Care India Limited. This amalgamation is expected to create one of India's top three hospital chains, significantly expanding the footprint to 9 states and 25 cities. Management anticipates the merger will be accretive to both Earnings Per Share (EPS) and EBITDA margins. The tribunal has dispensed with the requirement for a meeting of secured creditors, streamlining the approval process.
Key Highlights
NCLT directed shareholder and unsecured creditor meetings to be held between Feb 27 and March 13, 2026.
The merger aims to position the combined entity among the top 3 hospital chains in India with presence in 25 cities.
Aster DM's paid-up share capital as of Sept 30, 2025, stands at ₹518.12 crore across 51.81 crore equity shares.
Quality Care India Limited has a paid-up share capital of ₹380.92 crore and operates multi-specialty hospitals in India and Bangladesh.
Management expects the deal to be financially accretive to EPS and EBITDA margins for existing shareholders.
💼 Action for Investors
Investors should vote in favor of the merger during the upcoming March 2026 meeting as it provides significant scale and financial synergies. Monitor the post-merger integration plan and updated guidance on EPS accretion following the shareholder approval.
Aster DM Healthcare Increases Stake in Prerana Hospital to 98.92% for ₹38.36 Crore
Aster DM Healthcare has acquired an additional 11.94% stake in its subsidiary, Prerana Hospital Limited, for a cash consideration of ₹38.36 crore. This transaction increases Aster's total shareholding from 87% to 98.92%, moving closer to making it a wholly-owned subsidiary. Prerana Hospital has shown strong growth, with turnover rising from ₹98.92 crore in FY23 to ₹145.05 crore in FY25. The company expects to acquire the remaining 1.08% stake by December 31, 2026.
Key Highlights
Acquired 11.94% additional equity stake in Prerana Hospital Limited for ₹38.36 crore
Total shareholding in the subsidiary increased from 87% to 98.92%
Prerana Hospital reported a turnover of ₹145.05 crore for FY 2024-25
Target entity turnover has grown at a CAGR of approximately 21% over the last two years
Final 1.08% stake acquisition scheduled for completion by December 31, 2026
💼 Action for Investors
Investors should view this as a positive consolidation of a growing healthcare asset that strengthens Aster's portfolio. No immediate action is required, but the hospital's improving revenue trend is a good sign for long-term value.